IMR Press / EJGO / Volume 25 / Issue 5 / pii/2004240

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Is adjuvant therapy necessary for peritoneal cytology-positive surgical-pathologic Stage I endometrial cancer? Preliminary results

Show Less
1 Department of Obstetrics & Gynecology, Gynecologic Oncology Unit, Ankara (Turkey)
2 Department of Radiation Oncology, Culhane Military Medical Academy, Ankara (Turkey)
Eur. J. Gynaecol. Oncol. 2004, 25(5), 591–593;
Published: 10 October 2004
Abstract

Objective: To compare the clinical and laboratory findings between adjuvant therapy performed and not performed on peritoneal cytology-positive patients with cytology-negative cases of surgical-pathologic Stage I endometrial cancer. Methods: Twelve peritoneal cytology-positive and 12 negative surgical-pathologic Stage I endometrial cancer cases were used in the study. Adjuvant radiotherapy was performed for six cytology-positive patients (group I); no adjuvant therapy was performed for six cytology-positive (group II) and 12 cytology-negative patients (control group). Pelvic examination, vaginal cytology, serum CA125 levels and routine blood tests were checked at two-month intervals for two years and at six-month intervals for the third year. Abdominopelvic computerized tomography was planned annually. Results: There was no statistically significant difference among the three groups and no recurrence in any group. Conclusion: We do not recommend adjuvant therapy for cytology-positive patients if the tumor is confined to the uterus.

Keywords
Endometrial cancer
Peritoneal cytology
Adjuvant therapy
Share
Back to top